Kiran Mazumdar ShowKiran Mazumdar Shaw, CEO, Biocon and Biocon Biologics.

Biocon and its subsidiary Biocon Biologics recently announced their results in July and September. Kiran Mazumdar Shaw, CEO of Biocon and Biocon Biologics, discussed the company’s performance and other aspects in an interview with FE. Excerpts:

How will the alliance with the Serum Institute improve the performance of Biocon Biologics?

The alliance with Serum Institute Life Sciences (SILS) Biocon Biologics provides essential light and rapid entry into the vaccine sector. Vaccines are a convenient complement to Biocon Biologics, providing a new dimension to its efforts to improve global healthcare and an additional growth pillar.

The alliance provides Biocon Biologics with access to 100 million doses of SILS vaccines annually for 15 years and marketing rights to the SILS vaccine portfolio for a 15% stake. This will ensure Biocon Biologics a committed revenue stream with relevant profit margins beginning in the second half of FY23. The alliance’s near-term focus will be on Covid-19 vaccines. We will also gain access to the current development pipeline for SILS in other infectious diseases such as mosquito-borne infections. We will also be able to add next-generation vaccines, which will drive growth in the long run.

It has also partnered with Adagio Therapeutics to develop Covid drugs. With the Covid-19 virus on its way to waning, how do you see its prospects?

Biocon Biologics has partnered with Adagio Therapeutics to manufacture and market ADG20, a new anti-Covid-19 antibody therapy in several emerging markets across the Gulf Cooperation Council (GCC) and Asia, including India. This treatment will likely provide convenient outpatient management as a single intramuscular injection for the prevention and treatment of Covid-19. It is also designed to have a long half-life, allowing immediate and permanent protection against Covid-19 for up to one year.

ADG20 also has the ability to neutralize a wide range of emerging variants of SARS-CoV-2. The company is currently conducting phase 2/3 of pivotal trials to support the implementation of an Emergency Use Authorization (EUA) in the United States by the first quarter of 2022.

Biocon Biologics will gain access to clinical and non-clinical data from Adagio’s submission of EUA to the US Food and Drug Administration for approvals in emerging markets. Adagio has published six months of data from its ongoing Phase 1 trial in healthy volunteers (beginning in February 2021), supporting its safety and efficacy. Data on serum virus neutralization activity is equal to or better than that of some advanced Covid-19 vaccines.

We expect this partnership to help us advance our capabilities in infectious diseases and make a meaningful impact by improving access to Covid-19 medicines.

Get live stock quotes from BSE, NSE, US market and latest NAV, mutual fund portfolio, see the latest underwriting news, best IPOs, calculate tax by income tax calculator, see top market gainers, biggest losers and best stock funds. like us Facebook social networking site and follow us Twitter.

Financial Express is now available on Telegram. Click here to join our channel And stay up-to-date with the latest Biz news and updates.

Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *